News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Conference News EuroPCR 2023 Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization Michael O'Riordan May 19, 2023
News Conference News EuroPCR 2021 Elective Revascularization, Better Long-term Survival: Meta-analysis Michael O'Riordan May 18, 2021
News Conference News TCT 2020 Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care Michael O'Riordan October 19, 2020
News Conference News EuroPCR 2020 No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms Michael O'Riordan June 26, 2020
News Conference News AHA 2019 More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA Michael O'Riordan November 14, 2019
News Conference News TCT 2018 Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos Michael O'Riordan October 02, 2018
News Conference News EuroPCR 2018 ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics Michael O'Riordan May 31, 2018
News Conference News EuroPCR 2018 Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions Michael O'Riordan May 23, 2018
News Conference News EuroPCR 2018 FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis Michael O'Riordan May 22, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News AHA 2017 Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List Michael O'Riordan November 12, 2017